Day: August 3, 2020

BOSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) — Today DraftKings Inc. (Nasdaq: DKNG) announced it is expanding its daily fantasy sports (DFS) offerings to include the game variant Best Ball, with snake drafts. DraftKings also announced a $3M marquee tournament ahead of the 2020 NFL season, with a $1M top prize. As DraftKings’ first foray into a season-long product, Best Ball maintains fans’ connection to the DraftKings’ fantasy sports experience, while answering to a more nostalgic, season-long form.The streamlined draft format removes traditional DFS roster management, enabling customers to lock in player selections at the start of the season. As major U.S. sports leagues continue to return to the national stage, Best Ball furthers DraftKings’ reputation as being in-tune with the American sports fan, and offers customers a new opportunity...

DALLAS, Aug. 03, 2020 (GLOBE NEWSWIRE) — Primoris Services Corporation (NASDAQ Global Select: PRIM) (“Primoris” or “Company”) today announced two new solar awards with a combined value over $60 million.  The contracts were secured by the Power, Industrial, & Engineering segment. The awards are for the engineering, procurement, and construction of utility-scale solar facilities in the South.  The scope of work includes foundations, electrical, mechanical, and civil construction.Work will commence in the third quarter of 2020, and completion is expected in the third quarter of 2021.ABOUT PRIMORISFounded in 1960, Primoris, through various subsidiaries, has grown to become one of the leading providers of specialty contracting services operating mainly in the United States and Canada. Primoris provides a wide range of specialty...

SPRINGDALE, Ark., Aug. 03, 2020 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, today reported the following results:1 Adjusted operating income and adjusted net income per share attributable to Tyson, or Adjusted EPS, are non-GAAP financial measures and are explained and reconciled to a comparable GAAP measure at the end of this release.First Nine Months HighlightsGAAP EPS of $3.96, down 12% from prior year; Adjusted EPS of $3.83, down 10% from prior yearGAAP operating income of $2,102 million; Adjusted operating income of $2,155 millionTotal Company GAAP operating margin of 6.6% and Adjusted operating margin of 6.8%Generated $2.7 billion...

JOHNS CREEK, Ga., Aug. 03, 2020 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, healthcare and e-learning industries today announced that the Company will report its 2020 second quarter results on Friday, August 7th, 2020, and will host an investor conference call at 11:00 am ET on the same day to discuss the Company’s performance. The call is open to the public.Conference Call, Webcast and Replay Details:Call Date/Time:                       August 7th, 2020 at 11:00 a.m. ETCall Dial-In Toll Free:             +1 (877) 837-3909International Dial-In:              +1 (973) 409-9690Call ID:                                    # 8575679Live Audio Webcast:       https://edge.media-server.com/mmc/p/t96nb8b2 Audio Replay URL: ...

WALTHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2020.Clinical Pipeline UpdateRoluperidoneOn May 29, 2020, the Company announced that the Phase 3 trial of roluperidone to treat negative symptoms in schizophrenia did not meet its primary (reduction in PANSS Marder Negative Symptoms Factor Score or NSFS) and key secondary (improvement in the Personal and Social Performance Scale Total Score or PSP) endpoints.Although limited inferences can be drawn from these data, unadjusted statistically significant separations from placebo were observed in NSFS at Week 4 for both doses...

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the second quarter ended June 30, 2020 before the U.S. financial markets open on Monday, August 10, 2020.Management will host a conference call on August 10, 2020 at 8:30 a.m. ET to discuss these results and provide an update on the Company. Investors and participants can register for the call in advance by visiting http://dpregister.com/10146816. Upon registering, each participant will be provided with call details and a registrant ID. Alternatively, the conference call will be available via a live webcast. To access the live webcast or the replay,...

SAN JOSE, Calif. and NEW ORLEANS, Aug. 03, 2020 (GLOBE NEWSWIRE) — Align Technology, Inc. (NASDAQ: ALGN) makers of the Invisalign® clear aligner system, today announced a multi-year partnership with the New Orleans Saints, making the Invisalign brand the “Official Smile” partner of the Saints. The collaboration will focus on building awareness and generating demand for Invisalign treatment across social and digital platforms to engage consumers and highlight the benefits of in-office, doctor-delivered clear aligner treatment. Additionally, the Invisalign brand and the Saints have teamed up with defensive end Cam Jordan to bring more smiles to teens and young adults through the Youth Empowerment Project (YEP).“We are proud to be working with the New Orleans Saints to develop campaigns focused on winning smiles,” commented Frank Quinn,...

Connects consumers and Invisalign practices through network of NFL sponsored channels and supports youth initiatives championed by NFL ClubsBuilds on previously announced individual sponsorships with the New England Patriots and San Francisco 49ers – expands “Official Smile” roster to 11 NFL Clubs with the Dallas Cowboys, New Orleans Saints, Green Bay Packers, New York Giants, Kansas City Chiefs, Houston Texans, Philadelphia Eagles, Tampa Bay Buccaneers and the Chicago Bears.             SAN JOSE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) — Align Technology, Inc. (NASDAQ: ALGN) makers of the Invisalign® clear aligner system and the iTero® imaging systems, today announced an agreement with the National Football League (NFL) to make the Invisalign brand the Official Clear Aligner Sponsor of the NFL. Through this agreement, the Invisalign...

HONG KONG, Aug. 03, 2020 (GLOBE NEWSWIRE) — Futu Holdings Limited (“Futu” or the “Company”) (NASDAQ: FUTU), a leading tech-driven online brokerage and wealth management platform in China, today announced that it will report its financial results for the second quarter ended June 30, 2020, before U.S. markets open on August 13, 2020.Futu’s management will hold an earnings conference call on Thursday, August 13, 2020, at 8:00 AM U.S. Eastern Time (8:00 PM on the same day, Beijing/Hong Kong Time).Please note that all participants will need to pre-register for the conference call, using the link http://apac.directeventreg.com/registration/event/1560546. It will automatically lead to the registration page of “Futu Holdings Ltd Second Quarter 2020 Earnings Conference Call”, where details for RSVP are needed. When requested...

First-in-class TDP-43 antibody developed using SurpraAntigen™ platformThe only TDP-43 antibody with reported in vivo activityLAUSANNE, Switzerland, Aug. 03, 2020 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today announced the initiation of investigational new drug (IND)-enabling studies for the Company’s first-in-class therapeutic antibody targeting TDP-43 (TAR DNA-binding protein 43). The anti-TDP-43 antibody is the first therapeutic candidate shown to mitigate TDP-43 neuropathology in vivo and the Company plans to develop the antibody for the treatment of NeuroOrphan indications.Advancing the anti-TDP-43 antibody towards clinical development is the latest in a series of important milestones already achieved...